COO Cooper Companies Inc.

CooperCompanies Announces $2.14 Billion Senior Credit Facility and Amendment of $500 Million 364-Day Credit Facility

CooperCompanies Announces $2.14 Billion Senior Credit Facility and Amendment of $500 Million 364-Day Credit Facility

SAN RAMON, Calif., April 01, 2020 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE:COO) today announced the closing of a new five-year $2.14 billion senior unsecured credit facility, comprised of a $1.29 billion revolving line of credit and $850 million non-amortizing term loan. Proceeds from the refinancing will be used to retire all indebtedness under the Company’s existing $1.0 billion revolving line of credit and $1.0 billion term loan, as well as for general corporate purposes. The borrowing rates will be based on the Company’s leverage ratio, as defined in the Credit Agreement, and can range from LIBOR plus 0.75 percent to 1.5 percent. The initial borrowing rate is LIBOR plus 0.875 percent, which is 25 bps lower than the Company’s current borrowing rate. The Company also announced an amendment to its $500 million 364-day credit facility to match terms and conditions of the new facility where applicable. 

“We initiated this financing before COVID-19 became a pandemic, and I want to thank the banks who maintained their support during this time. In particular, KeyBank, which led the deal and did a fantastic job,” said President and CEO, Albert White. “This facility extends our maturity dates, reduces pricing and provides additional availability, reflecting the strength of Cooper.”

About CooperCompanies

CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit .

Contact:

Kim Duncan

Vice President, Investor Relations and Risk Management

925-460-3663

EN
01/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cooper Companies Inc.

Cooper Companies Inc: 1 director

Two Directors at Cooper Companies Inc bought 2,107 shares at between 0.000USD and 68.390USD. The significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over...

 PRESS RELEASE

CooperCompanies Announces Expanded Share Repurchase Program

CooperCompanies Announces Expanded Share Repurchase Program SAN RAMON, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today its Board of Directors has approved a $1 billion increase in the Company’s share repurchase program. The share repurchase program now totals $2 billion. “We are pleased to announce that our Board of Directors has authorized an increase to our share repurchase program,” said Al White, President and Chief Executive Officer. “This decision underscores the strength of our balance sheet and cas...

 PRESS RELEASE

CooperCompanies Announces Third Quarter 2025 Results

CooperCompanies Announces Third Quarter 2025 Results SAN RAMON, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal third quarter ended July 31, 2025. Revenue increased 6% year-over-year to $1,060.3 million. CooperVision (CVI) revenue up 6% to $718.4 million, and CooperSurgical (CSI) revenue up 4% to $341.9 million.GAAP diluted earnings per share (EPS) of $0.49, down $0.03 or 6% from last year's third quarter.Non-GAAP diluted EPS of $1.10, up $0.14 or 15% from last year's ...

 PRESS RELEASE

CooperCompanies to Participate in the Wells Fargo Healthcare Conferenc...

CooperCompanies to Participate in the Wells Fargo Healthcare Conference SAN RAMON, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today it will participate in the Wells Fargo Healthcare Conference on Wednesday, September 3, 2025. Al White, President and CEO, will represent the Company in a session scheduled at 3:00 PM ET. The webcast will be available to investors and other interested parties by accessing the CooperCompanies’ website at . About CooperCompaniesCooperCompanies (Nasdaq: COO) is a leading global me...

 PRESS RELEASE

CooperCompanies Announces Release Date for Third Quarter 2025

CooperCompanies Announces Release Date for Third Quarter 2025 SAN RAMON, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today it will report third quarter 2025 financial results on Wednesday, August 27, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 3665386. A simultaneous audio webcast and subsequent replay can be accessed at . About...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch